Warning letter
Hospira Inc: warning letter of Feb 14, 2017
FDA warning letter 506761 · Kansas City District Office
Key facts
| Reference number | 506761 |
|---|---|
| Company | Hospira Inc |
| Subject | CGMP/Drugs/Adulterated |
| Issue date | Feb 14, 2017 |
| Posted date | Feb 14, 2017 |
| Issuing office | Kansas City District Office |
| Product type | Drugs |
| CFR sections cited | 211.192, 314.98, 211.110(b), 211.110(d), 211.160(b), 211.113(b), 314.81(b)(1) |
| Inspection city | Mcpherson |
| Inspection ZIP | 67460 |
| Inspection start date | May 16, 2016 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: